Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Antti I, Nykänen"'
Autor:
Antti I. Nykänen, Andrea Mariscal, Allen Duong, Aadil Ali, Akihiro Takahagi, Xiaohui Bai, Guan Zehong, Betty Joe, Mamoru Takahashi, Manyin Chen, Hemant Gokhale, Hongchao Shan, David M. Hwang, Catalina Estrada, Jonathan Yeung, Tom Waddell, Tereza Martinu, Stephen Juvet, Marcelo Cypel, Mingyao Liu, John E. Davies, Shaf Keshavjee
Publikováno v:
Cells, Vol 13, Iss 10, p 859 (2024)
Lung transplantation results are compromised by ischemia–reperfusion injury and alloimmune responses. Ex vivo lung perfusion (EVLP) is used to assess marginal donor lungs before transplantation but is also an excellent platform to apply novel thera
Externí odkaz:
https://doaj.org/article/d7513c66d54a448fb8dd71f93efea334
Autor:
Lasse Myllylahti MD, Jussi Ropponen MD, PhD, Mikko Lax MD, Riitta Lassila MD, PhD, Antti I. Nykänen MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Objectives Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with thrombotic states including elevated coagulation factor VIII (FVIII). Pulmonary endarterectomy (PEA) is the main treatment for CTEPH, and efficient anticoagulation is
Externí odkaz:
https://doaj.org/article/5d4bfe9593564143ba6a4b55b9286a22
Autor:
Antti I. Nykänen, Andrea Mariscal, Allen Duong, Catalina Estrada, Aadil Ali, Olivia Hough, Andrew Sage, Bonnie T. Chao, Manyin Chen, Hemant Gokhale, Hongchao Shan, Xiaohui Bai, Guan Zehong, Jonathan Yeung, Tom Waddell, Tereza Martinu, Stephen Juvet, Marcelo Cypel, Mingyao Liu, John E. Davies, Shaf Keshavjee
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss , Pp 184-197 (2021)
Ex vivo lung perfusion (EVLP) is an excellent platform to apply novel therapeutics, such as gene and cell therapies, before lung transplantation. We investigated the concept of human donor lung engineering during EVLP by combining gene and cell thera
Externí odkaz:
https://doaj.org/article/5f4ede1ff6fa4056972c31e49b704115
Publikováno v:
Bioengineering, Vol 10, Iss 6, p 728 (2023)
Lung transplantation is often the only viable treatment option for a patient with end-stage lung disease. Lung transplant results have improved substantially over time, but ischemia-reperfusion injury, primary graft dysfunction, acute rejection, and
Externí odkaz:
https://doaj.org/article/a958134baf3c42fd85fdc116e3d7c715
Publikováno v:
Transplantation. 107:e122-e123
Autor:
L. Perakyla, Peter Raivio, Antti Huuskonen, Karl B. Lemström, Pekka Hämmäinen, Antti I. Nykänen, Christoffer Stark, Maija Halme
Publikováno v:
Scandinavian Cardiovascular Journal. 54:192-199
Objectives. Lung transplantation remains the only available treatment option for many end-stage lung diseases. We evaluated our long-term lung transplantation results and the impact of chronic lung allograft dysfunction (CLAD). Design. Adult de novo
Autor:
Antti I. Nykänen, Peter Raivio
Publikováno v:
The Annals of Thoracic Surgery. 114:e83-e84
Autor:
Antti I. Nykänen, Andrea Mariscal, Aadil Ali, Olivia Hough, Vinicius S. Michaelsen, Mingyao Liu, Marcelo Cypel, Shaf Keshavjee
Publikováno v:
The Journal of thoracic and cardiovascular surgery. 164(5)
Ex vivo lung perfusion (EVLP) is an excellent platform to evaluate donor lung function before transplantation, but novel methods are needed to accurately confirm transplant quality. Near-infrared fluorescence (NIRF) imaging with indocyanine green (IC
Autor:
L. Perakyla, Antti I. Nykänen, Risto Kesävuori, Anneli Piilonen, Peter Raivio, Christoffer Stark, Maija Halme
Publikováno v:
Clinical transplantationREFERENCES. 36(1)
BACKGROUND Chronic lung allograft dysfunction (CLAD) limits long-term survival after lung transplantation. Of the two subtypes, restrictive allograft syndrome (RAS) is characterized by a larger lung volume decrease and worse prognosis than bronchioli
Autor:
Matti Kankainen, Karl B. Lemström, Jyri Lommi, Kishor Dhaygude, Simo Syrjälä, Raimo Tuuminen, Anne Räisänen-Sokolowski, Antti I. Nykänen, E. Holmström, Janne J. Jokinen, Rainer Krebs, Ilkka Helanterä
Publikováno v:
Circulation. 140:627-640
Background: Ischemia-reperfusion injury may compromise the short-term and long-term prognosis after heart transplantation. Experimental studies show that simvastatin administered to the organ donor is vasculoprotective and inhibits cardiac allograft